

Reference number(s)
7371-D

This document applies to the following:

Formulary	Applies
Standard Control (SF)	<input type="checkbox"/>
Standard Control Choice (SCCF)	<input type="checkbox"/>
Preferred Drug Plan Design (PDPD)	<input type="checkbox"/>
Advanced Control Specialty (ACSF)	<input type="checkbox"/>
Advanced Control Specialty Choice (ACSCF)	<input type="checkbox"/>
Managed Medicaid Template (MMT)	<input type="checkbox"/>
Marketplace (MF)	<input type="checkbox"/>
Aetna Small Group Affordable Care Act (SG ACA)	<input type="checkbox"/>
Aetna Health Exchange (AHE)	<input type="checkbox"/>
Value (VF)	<input checked="" type="checkbox"/>

Formulary	Applies
New to Market (NTM)	<input type="checkbox"/>
Standard Formulary Chart (SFC)	<input checked="" type="checkbox"/>
Basic Control Chart Preferred Drug Plan Design (BCC PDPD)	<input type="checkbox"/>
Advanced Control Specialty Formulary Chart (ACSFC)	<input checked="" type="checkbox"/>
Value Formulary Chart (VFC)	<input checked="" type="checkbox"/>
Medical Benefit	<input type="checkbox"/>
Medical Benefit: Advanced Biosimilars First	<input type="checkbox"/>
Combined Benefit Management (CBM)	<input type="checkbox"/>
Combined Benefit Management Pharmacy (CBMP)	<input type="checkbox"/>
Medical Benefit Managed Medicaid (MMMB)	<input type="checkbox"/>

Exceptions Criteria

Neuromyelitis Optica Spectrum Disorder (NMOSD) Products

This document informs prescribers of preferred products and provides an exception process for targeted products through prior authorization.

These criteria were developed to align with the following: Value Formulary (VF) Standard Formulary Chart (SFC), Advanced Control Specialty Formulary Chart (ACSFC), Value Formulary Chart (VFC).

Plan Design Summary

This program applies to the NMOSD products specified in this document. Coverage for targeted products is provided based on clinical circumstances that would exclude the use of the preferred product and may be based on previous use of a product. The coverage review process will ascertain situations where a clinical exception can be made. This program applies to all members requesting treatment with Bkern and Soliris. This criteria applies to members who are new to treatment with Uplizna for the first time.

Each referral is reviewed based on all utilization management (UM) programs implemented for the client.

Table. NMOSD Products

Medications considered formulary or preferred on your plan may still require a clinical prior authorization review.

Reference number(s)
7371-D

	Products
Preferred	<ul style="list-style-type: none"> • Enspryng (satralizumab-mwge) • Epysqli (eculizumab-aagh)
Target	<ul style="list-style-type: none"> • Bkemv (eculizumab-aeeb) • Soliris (eculizumab) • Ultomiris (ravulizumab-cwvz) • Uplizna (inebilizumab-cdon)

Exception Criteria

This program applies to members requesting treatment for NMOSD.

Bkemv, Soliris

Coverage for the targeted product is provided when both of the following criteria are met:

- Member has had a documented intolerable adverse event to the preferred product, Epysqli, and the adverse event was not an expected adverse event attributed to the active ingredient as described in the prescribing information (i.e., known adverse reaction for both the reference product and biosimilar products).
- Member has a documented inadequate response or intolerable adverse event with Enspryng.

Ultomiris, Uplizna

Coverage for the targeted product is provided when any of the following criteria is met:

- Member is currently receiving treatment with a targeted product, excluding when the requested targeted product is obtained as samples or via manufacturer’s patient assistance programs.
- Member has a documented inadequate response or intolerable adverse event with both of the preferred products.

References

1. Bkemv [package insert]. Thousand Oaks, CA: Amgen Inc.; October 2024.
2. Enspryng [package insert]. South San Francisco, CA: Genentech, Inc.; March 2022.
3. Epysqli [package insert]. Republic of Korea: Samsung Bioepis Co., Ltd.; February 2025.
4. Soliris [package insert]. Boston, MA: Alexion Pharmaceuticals, Inc.; March 2025.
5. Ultomiris [package insert]. Boston, MA: Alexion Pharmaceuticals, Inc.; September 2024.
6. Uplizna [package insert]. Deerfield, IL: Horizon Therapeutics USA, Inc.; December 2025.